Regulation_NN
of_IN
gene_NN
expression_NN
with_IN
double-stranded_JJ
phosphorothioate_NN
oligonucleotides_NNS
._.

Alteration_NN
of_IN
gene_NN
transcription_NN
by_IN
inhibition_NN
of_IN
specific_JJ
transcriptional_JJ
regulatory_JJ
proteins_NNS
is_VBZ
necessary_JJ
for_IN
determining_VBG
how_WRB
these_DT
factors_NNS
participate_VBP
in_IN
cellular_JJ
differentiation_NN
._.

The_DT
functions_NNS
of_IN
these_DT
proteins_NNS
can_MD
be_VB
antagonized_VBN
by_IN
several_JJ
methods_NNS
,_,
each_DT
with_IN
specific_JJ
limitations_NNS
._.

Inhibition_NN
of_IN
sequence-specific_JJ
DNA-binding_JJ
proteins_NNS
was_VBD
achieved_VBN
with_IN
double-stranded_JJ
-LRB-_-LRB-
ds_NN
-RRB-_-RRB-
phosphorothioate_NN
oligonucleotides_NNS
that_WDT
contained_VBD
octamer_NN
or_CC
kappa_NN
B_NN
consensus_NN
sequences_NNS
._.

The_DT
phosphorothioate_JJ
oligonucleotides_NNS
specifically_RB
bound_VBD
either_CC
octamer_NN
transcription_NN
factor_NN
or_CC
nuclear_JJ
factor_NN
-LRB-_-LRB-
NF_NN
-RRB-_-RRB-
-_:
kappa_NN
B_NN
._.

The_DT
modified_VBN
oligonucleotides_NNS
accumulated_VBD
in_IN
cells_NNS
more_RBR
effectively_RB
than_IN
standard_JJ
ds_JJ
oligonucleotides_NNS
and_CC
modulated_VBD
gene_NN
expression_NN
in_IN
a_DT
specific_JJ
manner_NN
._.

Octamer-dependent_JJ
activation_NN
of_IN
a_DT
reporter_NN
plasmid_NN
or_CC
NF-kappa_NN
B-dependent_JJ
activation_NN
of_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
-LRB-_-LRB-
HIV_NN
-RRB-_-RRB-
enhancer_NN
was_VBD
inhibited_VBN
when_WRB
the_DT
appropriate_JJ
phosphorothioate_NN
oligonucleotide_NN
was_VBD
added_VBN
to_TO
a_DT
transiently_RB
transfected_VBN
B_NN
cell_NN
line_NN
._.

Addition_NN
of_IN
phosphorothioate_JJ
oligonucleotides_NNS
that_WDT
contained_VBD
the_DT
octamer_NN
consensus_NN
to_TO
Jurkat_NN
T_NN
leukemia_NN
cells_NNS
inhibited_VBD
interleukin-2_NN
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
secretion_NN
to_TO
a_DT
degree_NN
similar_JJ
to_TO
that_DT
observed_VBN
with_IN
a_DT
mutated_VBN
octamer_NN
site_NN
in_IN
the_DT
IL-2_NN
enhancer_NN
._.

The_DT
ds_JJ
phosphorothioate_NN
oligonucleotides_NNS
probably_RB
compete_VBP
for_IN
binding_NN
of_IN
specific_JJ
transcription_NN
factors_NNS
and_CC
may_MD
provide_VB
anti-viral_JJ
,_,
immunosuppressive_JJ
,_,
or_CC
other_JJ
therapeutic_JJ
effects_NNS
._.

